Concepts (117)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Papillary | 3 | 2019 | 584 | 0.600 |
Why?
|
| Radiology Department, Hospital | 1 | 2017 | 52 | 0.550 |
Why?
|
| Spinal Cord Compression | 1 | 2017 | 152 | 0.530 |
Why?
|
| Ambulatory Care Facilities | 1 | 2017 | 290 | 0.480 |
Why?
|
| Mucin-4 | 1 | 2012 | 18 | 0.430 |
Why?
|
| Spinal Neoplasms | 1 | 2017 | 632 | 0.400 |
Why?
|
| Receptors, Estrogen | 3 | 2013 | 2085 | 0.370 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2019 | 1219 | 0.360 |
Why?
|
| Breast Neoplasms | 6 | 2019 | 15709 | 0.260 |
Why?
|
| Receptor, ErbB-2 | 2 | 2019 | 2519 | 0.230 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2021 | 60 | 0.190 |
Why?
|
| Mouth | 1 | 2021 | 122 | 0.180 |
Why?
|
| Veterans Health | 1 | 2021 | 181 | 0.170 |
Why?
|
| Carbon Isotopes | 1 | 2019 | 332 | 0.160 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2012 | 5183 | 0.160 |
Why?
|
| Cell-Matrix Junctions | 1 | 2015 | 9 | 0.130 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2015 | 85 | 0.120 |
Why?
|
| Twist-Related Protein 1 | 1 | 2015 | 127 | 0.120 |
Why?
|
| Glucose | 1 | 2019 | 1247 | 0.110 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2021 | 1108 | 0.110 |
Why?
|
| Ambulatory Care | 1 | 2017 | 556 | 0.110 |
Why?
|
| Extracellular Matrix | 1 | 2015 | 544 | 0.100 |
Why?
|
| Estrogen Antagonists | 1 | 2012 | 183 | 0.100 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2022 | 1833 | 0.100 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 1165 | 0.090 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2015 | 676 | 0.090 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 14913 | 0.090 |
Why?
|
| Veterans | 1 | 2021 | 1685 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 15874 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 980 | 0.090 |
Why?
|
| Trastuzumab | 1 | 2012 | 697 | 0.090 |
Why?
|
| SEER Program | 1 | 2013 | 1000 | 0.090 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2015 | 973 | 0.090 |
Why?
|
| Survival Analysis | 2 | 2019 | 9195 | 0.080 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 1750 | 0.080 |
Why?
|
| Tamoxifen | 1 | 2012 | 875 | 0.080 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2019 | 1754 | 0.080 |
Why?
|
| Quinazolines | 1 | 2012 | 924 | 0.070 |
Why?
|
| Gene Expression | 2 | 2012 | 3563 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 1 | 2022 | 3975 | 0.070 |
Why?
|
| Female | 10 | 2022 | 142293 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2022 | 7717 | 0.070 |
Why?
|
| Carrier Proteins | 1 | 2015 | 2022 | 0.070 |
Why?
|
| Cartilage, Articular | 1 | 2006 | 70 | 0.070 |
Why?
|
| Nasal Septum | 1 | 2006 | 46 | 0.070 |
Why?
|
| Tumor Burden | 1 | 2012 | 1991 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 2504 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2012 | 2450 | 0.070 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 13669 | 0.070 |
Why?
|
| Middle Aged | 7 | 2021 | 86544 | 0.070 |
Why?
|
| Mice, Nude | 1 | 2012 | 4303 | 0.060 |
Why?
|
| Retrospective Studies | 5 | 2022 | 38011 | 0.060 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 3317 | 0.060 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 4845 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 3818 | 0.060 |
Why?
|
| Transcriptome | 1 | 2012 | 1863 | 0.060 |
Why?
|
| Cell Line, Tumor | 3 | 2015 | 14561 | 0.060 |
Why?
|
| Incidence | 1 | 2013 | 5713 | 0.050 |
Why?
|
| Humans | 11 | 2022 | 262248 | 0.050 |
Why?
|
| Prognosis | 3 | 2019 | 21737 | 0.050 |
Why?
|
| Texas | 1 | 2013 | 6308 | 0.050 |
Why?
|
| Cystoscopy | 1 | 2022 | 88 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2019 | 5100 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 2334 | 0.050 |
Why?
|
| Glossectomy | 1 | 2021 | 40 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 3263 | 0.050 |
Why?
|
| Phenotype | 1 | 2012 | 6255 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2019 | 7793 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 3983 | 0.050 |
Why?
|
| Laryngectomy | 1 | 2021 | 241 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2021 | 33028 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2022 | 11571 | 0.040 |
Why?
|
| Survival Rate | 1 | 2013 | 12239 | 0.040 |
Why?
|
| Collagen | 2 | 2015 | 737 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 6223 | 0.040 |
Why?
|
| Radiography | 1 | 2022 | 1900 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 5009 | 0.040 |
Why?
|
| Risk | 1 | 2021 | 1974 | 0.040 |
Why?
|
| Free Tissue Flaps | 1 | 2021 | 372 | 0.040 |
Why?
|
| Mice | 2 | 2019 | 34393 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2021 | 2231 | 0.030 |
Why?
|
| Animals | 3 | 2019 | 59489 | 0.030 |
Why?
|
| Elasticity | 1 | 2015 | 156 | 0.030 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2015 | 321 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2012 | 11972 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 10348 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 2236 | 0.030 |
Why?
|
| Male | 3 | 2021 | 123338 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2015 | 746 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 10021 | 0.030 |
Why?
|
| Registries | 1 | 2019 | 2188 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 2420 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2015 | 1865 | 0.020 |
Why?
|
| Algorithms | 1 | 2022 | 3890 | 0.020 |
Why?
|
| RNA Interference | 1 | 2015 | 1411 | 0.020 |
Why?
|
| Aged | 4 | 2021 | 70367 | 0.020 |
Why?
|
| Transfection | 1 | 2015 | 2934 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 8885 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 984 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 1435 | 0.020 |
Why?
|
| Time Factors | 2 | 2015 | 12984 | 0.020 |
Why?
|
| Endopeptidase K | 1 | 2006 | 6 | 0.020 |
Why?
|
| Compressive Strength | 1 | 2006 | 17 | 0.020 |
Why?
|
| Glycosaminoglycans | 1 | 2006 | 61 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 29996 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 7218 | 0.020 |
Why?
|
| Cell Membrane Permeability | 1 | 2006 | 122 | 0.020 |
Why?
|
| Anisotropy | 1 | 2006 | 182 | 0.020 |
Why?
|
| Hydrolysis | 1 | 2006 | 229 | 0.020 |
Why?
|
| Temperature | 1 | 2006 | 508 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 3450 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 4323 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2015 | 2860 | 0.020 |
Why?
|
| Tissue Engineering | 1 | 2006 | 269 | 0.010 |
Why?
|
| Adult | 3 | 2019 | 78179 | 0.010 |
Why?
|
| Young Adult | 1 | 2019 | 21494 | 0.010 |
Why?
|
| Adolescent | 1 | 2006 | 31239 | 0.000 |
Why?
|